Brand Loyalty and Generic Entry: Why do Brand-Name Drug Companies Launch Their Own Generics?

IF 1.5 4区经济学 Q2 ECONOMICS

Japanese Economic Review Pub Date : 2018-07-08 DOI:10.1111/jere.12189

Yunyun Wan

引用次数: 1

Abstract

Facing generic competition, brand-name drug companies sometimes launch their own generics called “authorised generics” (AGs) through a third-party entity. If that strategy works, an AG should be launched for every branded drug that comes off patent. This, however, contradicts the fact that only a small proportion of branded drugs have had AGs. To explain this puzzle, I develop a two-period model in which a brand-name drug company exploits its name brand before generic entry. The model predicts that the brand-name company launches an AG only when brand loyalty is sufficiently weak.

查看原文本刊更多论文

品牌忠诚度和仿制药准入:为什么名牌药公司推出自己的仿制药?

面对仿制药的竞争，品牌药公司有时会通过第三方实体推出自己的仿制药，称为“授权仿制药”(AGs)。如果这一策略奏效，那么每一种专利到期的品牌药物都应该成立一个AG。然而，这与只有一小部分品牌药物含有AGs的事实相矛盾。为了解释这个谜题，我开发了一个两期模型，在这个模型中，一家知名制药公司在仿制药进入市场之前利用自己的品牌。该模型预测，只有当品牌忠诚度足够弱时，品牌公司才会推出AG。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Economic Review ECONOMICS-

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： Started in 1950 by a group of leading Japanese economists under the title The Economic Studies Quarterly, the journal became the official publication of the Japanese Economic Association in 1959. As its successor, The Japanese Economic Review has become the Japanese counterpart of The American Economic Review, publishing substantial economic analysis of the highest quality across the whole field of economics from researchers both within and outside Japan. It also welcomes innovative and thought-provoking contributions with strong relevance to real economic issues, whether political, theoretical or policy-oriented.